Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vantia Therapeutics appoints new CEO

This article was originally published in Scrip

Executive Summary

Vantia Therapeutics (UK) has named Andrew Crockett chief executive officer. He joined the company in 2009 as vice-president of business development from the US speciality pharma firm ZARS Pharma. Vantia, which was formed in 2008 as a spin-out of Ferring Research's small-molecule R&D, has two clinical phase products – VA106483 for the treatment of nocturia and VA111913 for the treatment of dysmenorrhoea.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC009111

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel